Background
Methods
Patients
Genetic testing
Statistical analysis
Results
Osteonecrosis N=68 | Idiopathic osteonecrosis n=45 | Secondary osteonecrosis n=23 | |
---|---|---|---|
Gender (men/women) | 56/12 (82,35%/17,65%) | 38/7 (84,44%/15,56%) | 18/5 (78,26%/21,74%) |
Age (years) | 44,98 (15-77) | 44,42 (15-77) | 46,08 (20-74) |
Bilateral ONFH | 39 (57,35%) | 23 (51,11%) | 16 (69,56%) |
Smoking | 27 (39,7%) | 21 (46,66%) | 6 (26,06%) |
Diabetes mellitus | 8 (11,76%) | 4 (8,88%) | 4 (17,39%) |
Coronary disease | 3 (4,41%) | 2 (4,44%) | 1 (4,34%) |
Thrombosis | 1 (1,47%) | 0 | 1 (4,34%) |
Leriche syndrome | 1 (1,47%) | 1 (2,22%) | 0 |
Hypertension | 13 (19,11%) | 8 (17,77%) | 5 (21,73%) |
Hyperlipidemia | 1 (1,47%) | 1 (2,22%) | 0 |
Allele | Controls N=200 | Patients | ||
---|---|---|---|---|
Total N=136 | Idiopathic n=90 | Secondary n=46 | ||
Factor V Leiden | ||||
A | 0,03 | 0,0225 | 0,0333 | 0 |
G | 0,97 | 0,9775 | 0,9667 | 1,0 |
Prothrombin | ||||
A | 0,01 | 0,0074 | 0 | 0,0218 |
G | 0,99 | 0,9926 | 1,0 | 0,9782 |
MTHFR | ||||
T | 0,28 | 0,3161 | 0,3444 | 0,2608 |
C | 0,72 | 0,6839 | 0,6556 | 0,7392 |
TPA | ||||
D | 0,365 | 0,4705a
| 0,5111b
| 0,3478 |
I | 0,6350 | 0,5295 | 0,4889 | 0,6522 |
Genotype | Controls N=100 | Patients | ||
---|---|---|---|---|
Total N=68 | Idiopathic n=45 | Secondary n=23 | ||
Factor V Leiden | ||||
GA | 3(3%) | 3(4,41%) | 3(6,67%) | 0 |
GG | 97(97%) | 65(95,59%) | 42(93,33%) | 23(100%) |
Prothrombin | ||||
GA | 2(2%) | 1(1,47%) | 0 | 1(4,35%) |
GG | 98(98%) | 67(98,53%) | 45(100%) | 22(95,65%) |
MTHFR | ||||
TT | 7(7%) | 4(5,88%) | 4(8,89%) | 0 |
CT | 42(42%) | 35(51,47%) | 23(51,11%) | 12(52,17%) |
CC | 51(51%) | 29(42,65%) | 18(40%) | 11(47,83%) |
TPA | ||||
DD | 18(18%) | 13(19,12%) | 11(24,44%)a
| 2(8,7%) |
ID | 37(37%) | 38(55,88%)b
| 24(53,33%)c
| 14(60,87%) |
II | 45(45%) | 17(25%) | 10(22,22%) | 7(30,43%) |
Allele | Controls N=200 | Patients | ||
---|---|---|---|---|
Total N=136 | Female n=24 | Male n=112 | ||
Factor V Leiden | ||||
A | 0,03 | 0,0225 | 0 | 0,0267 |
G | 0,97 | 0,9775 | 1,0 | 0,9733 |
Prothrombin | ||||
A | 0,01 | 0,0074 | 0 | 0,0089 |
G | 0,99 | 0,9926 | 1,0 | 0,9911 |
MTHFR | ||||
T | 0,28 | 0,3161 | 0,4583 | 0,2857 |
C | 0,72 | 0,6839 | 0,5417 | 0,7143 |
TPA | ||||
D | 0,365 | 0,4705a
| 0,3636 | 0,5b
|
I | 0,6350 | 0,5295 | 0,6364 | 0,5 |
Genotype | Controls N=100 | Patients | ||
---|---|---|---|---|
Total N=68 | Female n=12 | Male n=56 | ||
Factor V Leiden | ||||
GA | 3(3%) | 3(4,41%) | 0 | 3(5,66%) |
GG | 97(97%) | 65(95,59%) | 12(100%) | 53(94,34%) |
Prothrombin | ||||
GA | 2(2%) | 1(1,47%) | 0 | 1(1,78%) |
GG | 98(98%) | 67(98,53%) | 12(100%) | 55(98,22%) |
MTHFR | ||||
TT | 7(7%) | 4(5,88%) | 2(18,66%) | 2(3,57%) |
CT | 42(42%) | 35(51,47%) | 7(56,34%) | 28(50,01%) |
CC | 51(51%) | 29(42,65%) | 3(25%) | 26(46,42%) |
TPA | ||||
DD | 18(18%) | 13(19,12%) | 2(16,66%) | 11(19,64%) |
ID | 37(37%) | 38(55,88%)a
| 4(33,34%) | 34(60,72%)b
|
II | 45(45%) | 17(25%) | 6(50,0%) | 11(19,64%) |
Allele | Controls N=200 | Patients | ||
---|---|---|---|---|
Total N=136 | <50 n=86 | >50 n=50 | ||
Factor V Leiden | ||||
A | 0,03 | 0,0225 | 0,0117 | 0,041 |
G | 0,97 | 0,9775 | 0,9883 | 0,959 |
Prothrombin | ||||
A | 0,01 | 0,0074 | 0,0117 | 0 |
G | 0,99 | 0,9926 | 0,9883 | 1,0 |
MTHFR | ||||
T | 0,28 | 0,3161 | 0,267 | 0,38 |
C | 0,72 | 0,6839 | 0,733 | 0,62 |
TPA | ||||
D | 0,365 | 0,4705a
| 0,4302 | 0,54b
|
I | 0,6350 | 0,5295 | 0,5698 | 0,46 |
Genotype | Controls N=100 | Patients | ||
---|---|---|---|---|
Total N=68 | <50 n=43 | >50 n=25 | ||
Factor V Leiden | ||||
GA | 3(3%) | 3(4,41%) | 3(6,67%) | 0 |
GG | 97(97%) | 65(95,59%) | 40(93,33%) | 25(100%) |
Prothrombin | ||||
GA | 2(2%) | 1(1,47%) | 1 (2,38%) | 0 |
GG | 98(98%) | 67(98,53%) | 42(97,62%) | 25(100%) |
MTHFR | ||||
TT | 7(7%) | 4(5,88%) | 1(2,32%) | 3(12%) |
CT | 42(42%) | 35(51,47%) | 22(51,16%) | 13(52%) |
CC | 51(51%) | 29(42,65%) | 20(46.52%) | 9(36%) |
TPA | ||||
DD | 18(18%) | 13(19,12%) | 8(18,6%) | 5(20%) |
ID | 37(37%) | 38(55,88%)a
| 21(48.83%) | 17(68%)b
|
II | 45(45%) | 17(25%) | 14(32,57%) | 3(12%) |
Allele | Controls N=200 | Patients | ||
---|---|---|---|---|
Total N=136 | Unilateral n=58 | Bilateral n=78 | ||
Factor V Leiden | ||||
A | 0,03 | 0,0225 | 0,0334 | 0,0128 |
G | 0,97 | 0,9775 | 0,9656 | 0,9872 |
Prothrombin | ||||
A | 0,01 | 0,0074 | 0,0175 | 0 |
G | 0,99 | 0,9926 | 0,9825 | 1,0 |
MTHFR | ||||
T | 0,28 | 0,3161 | 0,3103 | 0,3205 |
C | 0,72 | 0,6839 | 0,6897 | 0,6795 |
TPA | ||||
D | 0,365 | 0,4705a
| 0,3965 | 0,5256b
|
I | 0,6350 | 0,5295 | 0,6035 | 0,4744 |
Genotype | Controls N=100 | Patients | ||
---|---|---|---|---|
Total N=68 | Unilateral n=29 | Bilateral n=39 | ||
Factor V Leiden | ||||
GA | 3(3%) | 3(4,41%) | 2(6,89%) | 1(2,56%) |
GG | 97(97%) | 65(95,59%) | 27(93,11%) | 38(97,44%) |
Prothrombin | ||||
GA | 2(2%) | 1(1,47%) | 1(3,44%) | 0 |
GG | 98(98%) | 67(98,53%) | 28(96,56%) | 39(100%) |
MTHFR | ||||
TT | 7(7%) | 4(5,88%) | 2(6,89%) | 2(5,12%) |
CT | 42(42%) | 35(51,47%) | 14(48,27%) | 21(53,84%) |
CC | 51(51%) | 29(42,65%) | 13(44,84%) | 16(41,04%) |
TPA | ||||
DD | 18(18%) | 13(19,12%) | 3(10,34%) | 10(25,64%)a
|
ID | 37(37%) | 38(55,88%)b
| 17(58,62%) | 21(53,84%)c
|
II | 45(45%) | 17(25%) | 9(31,04%) | 8(20,52%) |